Your Messages Inbox
Your Article Summary
See Latest ArticlesBioMimetic Therapeutics Reports 2008 Fourth Quarter and Year End Results
BioMimetic Therapeutics, 03/13/09
Results were also announced from the Swedish pilot study investigating the use of Augment Injectable for the treatment of distal radius fractures. In the 21 patient, randomized, controlled study evaluating distal radius fractures treated with external fixation versus external fixation combined with Augment Injectable, patients treated with Augment Injectable demonstrated earlier bone formation at three and six weeks as measured by CT scans. The six month evaluation of complete bone fill was 100% for Augment Injectable patients, as compared with 82% for the control group. The product candidate was demonstrated to be safe, with no reported adverse events related to the study devices.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
PR distribution service for the biotech industry
b3c newswire, 12/07/09
Safety First in Biotech Development
BioPharm, 12/03/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Article Search
Sponsor